AUGUST 29, 2023
Microbiota-Based Therapy for the Prevention of Recurrent Clostridioides difficile Infection:
A Primer on REBYOTA®
(fecal microbiota, live-jslm)
This Special Report outlines the challenges of treating Clostridioides difficile infection (CDI) and preventing recurrent CDI, and introduces REBYOTA (fecal-microbiota, live jslm), the first and only single-dose, FDA-approved, microbiota-based live biotherapeutic indicated for prevention of rCDI, as a potential option in restoring the gut microbiome.
Download to read this article in PDF format:
Microbiota-Based Therapy for the Prevention of Recurrent Clostridioides difficile Infection: A Primer on REBYOTA®(fecal microbiota, live-jslm)
This article is in PDF format and it requires Adobe Reader.
If you do not have Adobe Reader installed on your computer then please download and install from the link below.
Download Adobe Reader